DelveInsight's "Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Retinitis Pigmentosa market report provides current treatment practices, emerging drugs, Retinitis Pigmentosa market share of the individual therapies, current and forecasted Retinitis Pigmentosa market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Retinitis Pigmentosa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms. Based on clinical impact, RP is classified into three categories that include, non-syndromic, or "simple" (not affecting other organs or tissues), Syndromic (affecting other neurosensory systems such as hearing), and Systemic (affecting multiple tissues. Non-syndromic RP has three-stage: early stage, mid and end-stage. Non-syndromic RP is further subcategorized as autosomal dominant RP, autosomal recessive RP, X-linked RP, sporadic/simplex RP, and Leber congenital amaurosis (LCA).
Syndromic and Systemic RP are subcategorized into usher syndrome, bardet-biedl syndrome, and others.
Diagnosis
The diagnosis of RP is suspected in patients with poor night vision or family history (more than 40% of RP cases in the US have no family history). It relies upon documentation of rod dysfunction as measured by dark adaptation or electroretinogram, progressive loss in photoreceptor function, loss of peripheral vision and bilateral involvement.
The most common findings on ocular examination are usually preserved visual acuity until late-stage disease and reduced visual fields. Most adult patients have posterior subcapsular cataracts and visual acuity that varies from 20/20 to near blindness late in the disease.
Treatment
It covers the details of conventional and current medical therapies available in the Retinitis Pigmentosa (RP) market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the 7MM.
The DelveInsight’s Retinitis Pigmentosa (RP) market report gives a thorough understanding of Retinitis Pigmentosa (RP) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2030.
Key Findings
This section provides glimpses of the Retinitis Pigmentosa epidemiology in the 7MM market.
According to DelveInsight’s, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM was 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Country Wise- Retinitis Pigmentosa Epidemiology
The epidemiology segment also provides the Retinitis Pigmentosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Retinitis Pigmentosa report encloses the detailed analysis of Retinitis Pigmentosa marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the RP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Retinitis Pigmentosa Marketed Drugs
1. Luxturna: Spark Therapeutics/ Novartis
Luxturna (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells.
The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing Luxturna as per a licensing agreement covering the development, registration and commercialization rights of Luxturna in markets outside the US. It is indicated for the treatment of patients with vision loss due to Leber’s congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.
Products detail in the report…
Retinitis Pigmentosa Emerging Drugs
1. HORA-RPE65: Horama
Horama is developing a HORA-RPE65 gene replacement product for the treatment of RPE65 Retinitis Pigmentosa. It is an AAV 2/4 encapsidating the human RPE65 gene under the control of the human native RPE65 promoter. The company investigational candidate HORA-RPE65 provides the cell with a non-mutated copy of the human RPE65 gene, which can express functional RPE65 protein to halt or at least significantly delay retinal degeneration in patients with inherited retinal dystrophies caused by RPE65 gene mutations.
The drug is being delivered in the form of a sterile vector suspension injected directly into the subretinal space, where it induces transgene expression in retinal pigment epithelium cells. Horama had already completed a single-center, open, non-randomized phase I/II clinical trial which accessed the safety and effectiveness of HORA-RPE65 in patients with retinal dystrophy caused by RPE65 gene abnormalities.
Products detail in the report…
The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Retinitis Pigmentosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017–2030.
Key Findings
This section includes a glimpse of the Retinitis Pigmentosa 7MM market. The market size of Retinitis Pigmentosa in the 7MM market was USD 237.27 million in 2017.
The United States Market Outlook
This section provides the total Retinitis Pigmentosa market size and market size by therapies in the United States.
Among the 7MM countries, the United States had the highest market size of RP in 2017, which accounts for 56.40% of the total market. At present, the growth of market size for RP is attributed to support treatment regimens, the only approved therapy (Luxturna), as well as, emerging therapies. The market size for RP was found to be USD 133.82 million in 2017.
EU-5 Market Outlook
The total Retinitis Pigmentosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Germany accounts for 26.28% of the total EU-5 market of RP. DelveInsight’s estimates suggest that the overall market size of RP was observed to remain nearly constant from USD 20.90 million in 2017 to USD 21.33 million in 2018. This is attributed to the dependency of the market size of RP on supportive treatment regimens, at present. However, with the recent approval of Luxturna, the market size of RP is expected to experience a significant increase. The dearth of marketed treatment regimens for RP is the foremost unmet need of this therapeutic area, which is primarily responsible for nearly constant market size.
Japan Market Outlook
The total Retinitis Pigmentosa market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Retinitis Pigmentosa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Retinitis Pigmentosa market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Retinitis Pigmentosa key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Retinitis Pigmentosa emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Retinitis Pigmentosa domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Retinitis Pigmentosa market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Retinitis Pigmentosa Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
What is Retinitis Pigmentosa?
Retinitis Pigmentosa is defined as a large group of inherited vision disorders that cause progressive degeneration of the retina
What was the market size of Retinitis Pigmentosa in 2017?
Retinitis Pigmentosa Market Size in the 7MM was found to be USD 237.27 million in 2017
What are the Retinitis Pigmentosa market drivers?
Increasing R&D Activities, Market share, Raising Awareness and Novel Curative Therapies are the Retinitis Pigmentosa market drivers
What are the Retinitis Pigmentosa market barriers?
Lack of awareness about the disease, Complex Pathophysiology, Lack of Clinically Relevant Biomarker and High cost of therapy are the Retinitis Pigmentosa market barriers
Which companies are developing drugs for Retinitis Pigmentosa?
Horama, jCyte, Allergan, Dompé Farmaceutici, Neurotech Pharmaceuticals, ReNeuron Limited are developing drugs for Retinitis Pigmentosa
1. Key Insights
2. Executive Summary of Retinitis Pigmentosa (RP)
3. Retinitis Pigmentosa (RP): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of RP in 2017
3.2. Total Market Share (%) Distribution of RP in 2030
4. Retinitis Pigmentosa: Disease Background and Overview
4.1. Introduction
4.2. History
4.3. Facts about Retina
4.4. Signs and Symptoms
4.5. Causes of Retinitis Pigmentosa
4.6. Clinical Features
4.7. Classification of Retinitis Pigmentosa
4.7.1. Classification as per Japanese guidelines
4.8. Pathophysiology
4.9. Etiology
4.10. Genetics of Retinitis Pigmentosa
4.10.1. Types of non-syndromic RP inheritance
4.11. Diagnosis
4.11.1. Recommended Diagnostic Tests
4.11.2. Differential diagnosis of RP
5. Case Reports
5.1. A Case of Unilateral Retinitis Pigmentosa Associated with Full-Thickness Macular Hole
5.2. Eleven-Year Follow-Up of a Japanese Retinitis Pigmentosa Patient with an HK1 Gene Mutation
5.3. Unilateral Retinitis Pigmentosa: Visual field changes in a 31-year-old female
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM
6.4. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
6.5. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
6.6. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic Retinitis Pigmentosa in the 7MM
6.7. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM
7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United States
7.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
7.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
7.5. Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic RP in the United States
7.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United States
8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany
8.1.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
8.1.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
8.1.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany
8.1.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France
8.2.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
8.2.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
8.2.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France
8.2.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy
8.3.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
8.3.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
8.3.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy
8.3.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain
8.4.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
8.4.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
8.4.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain
8.4.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom
8.5.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
8.5.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
8.5.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the United Kingdom
8.5.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United Kingdom
9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan
9.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
9.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
9.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan
9.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan
10. Treatment Algorithm, Current Treatment, and Medical Practices
10.1. General recommendations for RP treatment
10.2. Current Treatment Modalities
10.3. Future Treatment modalities
11. Proposed Guidelines for Retinitis Pigmentosa
12. Unmet Needs
13. Marketed Products
13.1. Luxturna: Spark Therapeutics/ Novartis
13.1.1. Drug Description
13.1.2. Regulatory Milestones
13.1.3. Product Development Activities
13.1.4. Advantages and Disadvantages
13.1.5. Safety and Efficacy
13.1.6. Product Profile
14. Emerging Therapies
14.1. Key Cross Competition
14.2. HORA-RPE65: Horama
14.2.1. Product Description
14.2.2. Other development Activities
14.2.3. Product Profile
14.3. HORA-PDE6B: Horama
14.3.1. Product Description
14.3.2. Other development Activities
14.3.3. Clinical Development
14.3.4. Product Profile
14.4. AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen
14.4.1. Product Description
14.4.2. Other development Activities
14.4.3. Clinical Development
14.4.4. Safety and Efficacy
14.4.5. Product Profile
14.5. jCell: jCyte
14.5.1. Product Description
14.5.2. Other development Activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.5.5. Product Profile
14.6. Renexus: Neurotech
14.6.1. Product Description
14.6.2. Other Development Activities
14.6.3. Clinical Development
14.6.4. Product Profile
14.7. Cenegermin: Dompé Farmaceutici
14.7.1. Product Description
14.7.2. Other development Activities
14.7.3. Clinical Development
14.7.4. Safety and Efficacy
14.7.5. Product Profile
14.8. hRPC Cells : ReNeuron
14.8.1. Product Description
14.8.2. Other development Activities
14.8.3. Clinical Development
14.8.4. Safety and Efficacy
14.8.5. Product Profile
14.9. UshStat: Sanofi (Terminated)
14.9.1. Product Description
14.9.2. Other development Activities
14.9.3. Clinical Development
14.9.4. Safety and Efficacy
14.9.5. Product Profile
14.10. AGN-151597: Allergan
14.10.1. Product Description
14.10.2. Other development Activities
14.10.3. Clinical Development
14.10.4. Product Profile
14.11. AAV-RPGR: MeiraGTx
14.11.1. Product Description
14.11.2. Other development Activities
14.11.3. Clinical Development
14.11.4. Product Profile
14.12. AAV-RPE65: MeiraGTx
14.12.1. Product Description
14.12.2. Other development Activities
14.12.3. Clinical Development
14.12.4. Safety and Efficacy
14.12.5. Product Profile
15. Retinitis Pigmentosa (RP): 7MM Market Analysis
15.1. Key Findings
15.2. Market Estimation Methodology
15.3. Attribute Analysis
15.4. Market Size of Retinitis Pigmentosa in the 7MM
15.5. Market Size of Retinitis Pigmentosa by Therapies in the 7MM
15.6. Retinitis Pigmentosa: Emerging Market Competition
16. United States: Market Outlook
16.1. United States Market Size
16.1.1. Total Market size of Retinitis Pigmentosa in the United States
16.1.2. Market Size of Retinitis Pigmentosa by Therapies in the US
17. EU-5 countries: Market Outlook
17.1. Germany Market Size
17.1.1. Total Market size of Retinitis Pigmentosa in Germany
17.1.2. Market Size of Retinitis Pigmentosa by therapies in Germany
17.2. France Market Size
17.2.1. Total Market size of Retinitis Pigmentosa in France
17.2.2. Market Size of Retinitis Pigmentosa by therapies in France
17.3. Italy Market Size
17.3.1. Total Market size of Retinitis Pigmentosa in Italy
17.3.2. Market Size of Retinitis Pigmentosa by therapies in Italy
17.4. Spain Market Size
17.4.1. Total Market size of Retinitis Pigmentosa in Spain
17.4.2. Market Size of Retinitis Pigmentosa by therapies in Spain
17.5. United Kingdom Market Size
17.5.1. Total Market size of Retinitis Pigmentosa in the United Kingdom
17.5.2. Market Size of Retinitis Pigmentosa by therapies in the UK
18. Japan Market Outlook
18.1. Japan Market Size
18.1.1. Total Market size of Retinitis Pigmentosa in Japan
18.1.2. Market Size of Retinitis Pigmentosa by therapies in Japan
19. Access and Reimbursement Overview of Retinitis Pigmentosa
19.1. Current therapy–Luxturna
19.2. Outline of the Patient Journey with Luxturna Introduced by Spark Therapeutics
19.3. Coverage Parameters for Luxturna
19.4. Payer billing guidelines for claims processing and prompt payment of Luxturna
19.5. Future Potential Therapies
20. Market Drivers
21. Market Barriers
22. SWOT Analysis
23. Appendix
23.1. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Table 1 Summary of Retinitis Pigmentosa (RP) Market, Epidemiology, and Key Events (2017–2030)
Table 2 Summary of Genes Implicated in RP
Table 3 Syndromic retinitis pigmentosa
Table 4 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 5 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 6 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Table 7 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the 7MM (2017–2030)
Table 8 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017–2030)
Table 9 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017–2030)
Table 10 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017–2030)
Table 11 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017–2030)
Table 12 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017–2030)
Table 13 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017–2030)
Table 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017–2030)
Table 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Table 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Table 17 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017–2030)
Table 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017–2030)
Table 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017–2030)
Table 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Table 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Table 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017–2030)
Table 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017–2030)
Table 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017–2030)
Table 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Table 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Table 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017–2030)
Table 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017–2030)
Table 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017–2030)
Table 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Table 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Table 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017–2030)
Table 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017–2030)
Table 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017–2030)
Table 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Table 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Table 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017–2030)
Table 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017–2030)
Table 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017–2030)
Table 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Table 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Table 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017–2030)
Table 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017–2030)
Table 44 Associated conditions and corresponding treatment plans for RP Patients
Table 45 Key Cross of Emerging Drugs
Table 46 Key Cross of Emerging Drugs (Contd.)
Table 47 AAV8-RPGR, Clinical Trial Description, 2020
Table 48 AAV8-RPGR, Clinical Trial Description, 2020
Table 49 jCell, Clinical Trial Description, 2020
Table 50 Renexus (NT-501), Clinical Trial Description, 2020
Table 51 Cenegermin (rhNGF), Clinical Trial Description, 2020
Table 52 hRPC, Clinical Trial Description, 2020
Table 53 UshStat, Clinical Trial Description, 2020
Table 54 RST-001, Clinical Trial Description, 2020
Table 55 AAV-RPGR, Clinical Trial Description, 2020
Table 56 AAV RPE65, Clinical Trial Description, 2020
Table 57 Market Size of Retinitis Pigmentosa in 7MM in USD Million (2017–2030)
Table 58 Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017–2030)
Table 59 The US Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 60 Market Size of Retinitis Pigmentosa by therapies in the US, in USD Million (2017–2030)
Table 61 Expected Launch Date of Emerging Drugs in EU-5 countries
Table 62 Germany Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 63 Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017–2030)
Table 64 France Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 65 Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017–2030)
Table 66 Italy Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 67 Market Size of Retinitis Pigmentosa by therapies in Italy, in USD Million (2017–2030)
Table 68 Spain Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 69 Market Size of Retinitis Pigmentosa by therapies in Spain, in USD Million (2017–2030)
Table 70 The UK Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 71 Market Size of Retinitis Pigmentosa by therapies in the UK, in USD Million (2017–2030)
Table 72 Expected Launch Date of Emerging Drugs in Japan
Table 73 Japan Market Size of Retinitis Pigmentosa in USD Million (2017–2030)
Table 74 Market Size of Retinitis Pigmentosa by therapies in Japan, in USD Million (2017–2030)
Figure 1 Structure of Retina
Figure 2 Normal Eye Anatomy Versus Eye Anatomy in Retinitis Pigmentosa
Figure 3 Typical Symptoms associated with RP
Figure 4 Typical Symptoms associated with RP
Figure 5 Classification of RP
Figure 6 Specific clinical diagnosis of RP
Figure 7 Pathophysiology of RP
Figure 8 Altered Retinoid Cycle Metabolic Pathway
Figure 9 Types of non-syndromic based on the inheritance pattern
Figure 10 Pattern of autosomal dominant RP inheritance
Figure 11 Pattern of autosomal recessive RP inheritance.
Figure 12 Pattern of X-linked RP inheritance
Figure 13 Altered Retinoid Cycle Metabolic Pathway
Figure 14 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 15 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 16 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017–2030)
Figure 17 Sub-Type Specific Diagnosed Prevalence of syndromic & Systemic RP in the 7MM (2017–2030)
Figure 18 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the 7MM (2017–2030)
Figure 19 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017–2030)
Figure 20 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017–2030)
Figure 21 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017–2030)
Figure 22 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017–2030)
Figure 23 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the US (2017–2030)
Figure 24 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017–2030)
Figure 25 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Figure 26 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017–2030)
Figure 27 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017–2030)
Figure 28 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany (2017–2030)
Figure 29 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017–2030)
Figure 30 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Figure 31 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017–2030)
Figure 32 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017–2030)
Figure 33 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France (2017–2030)
Figure 34 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017–2030)
Figure 35 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Figure 36 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017–2030)
Figure 37 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017–2030)
Figure 38 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy (2017–2030)
Figure 39 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017–2030)
Figure 40 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Figure 41 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017–2030)
Figure 42 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017–2030)
Figure 43 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain (2017–2030)
Figure 44 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the UK (2017–2030)
Figure 45 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Figure 46 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the UK (2017–2030)
Figure 47 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017–2030)
Figure 48 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the UK (2017–2030)
Figure 49 Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017–2030)
Figure 50 Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017–2030)
Figure 51 Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa RP in Japan (2017–2030)
Figure 52 Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017–2030)
Figure 53 Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan (2017–2030)
Figure 54 Future Treatment Modalities for Retinitis Pigmentosa
Figure 55 Unmet Needs of Retinitis Pigmentosa
Figure 56 Market Size of Retinitis Pigmentosa in the 7MM in USD Million (2017–2030)
Figure 57 Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017–2030)
Figure 58 Market Size of Retinitis Pigmentosa in the US, USD Millions (2017–2030)
Figure 59 Market Size of Retinitis Pigmentosa by therapies in the US, in USD Million (2017–2030)
Figure 60 Market Size of Retinitis Pigmentosa in Germany, USD Millions (2017–2030)
Figure 61 Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017–2030)
Figure 62 Market Size of Retinitis Pigmentosa in France, USD Millions (2017–2030)
Figure 63 Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017–2030)
Figure 64 Market Size of Retinitis Pigmentosa in Italy, USD Millions (2017–2030)
Figure 65 Market Size of Retinitis Pigmentosa by therapies in Italy in USD Million (2017–2030)
Figure 66 Market Size of Retinitis Pigmentosa in Spain, USD Millions (2017–2030)
Figure 67 Market Size of Retinitis Pigmentosa by therapies in Spain in USD Million (2017–2030)
Figure 68 Market Size of Retinitis Pigmentosa in the UK, USD Millions (2017–2030)
Figure 69 Market Size of Retinitis Pigmentosa by therapies in the UK in USD Million (2017–2030)
Figure 70 Market Size of Retinitis Pigmentosa in Japan, USD Millions (2017–2030)
Figure 71 Market Size of Retinitis Pigmentosa by therapies in Japan in USD Million (2017–2030)
Figure 72 Diagnosis Coding
Figure 73 HCPCS Codes
Figure 74 Modifiers
Figure 75 C code
Figure 76 J code
Figure 77 J code
Figure 78 Market Drivers
Figure 79 Market Barriers
Figure 80 SWOT Analysis
